{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:12:55Z","timestamp":1776168775151,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["DG25H300002"],"award-info":[{"award-number":["DG25H300002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR24H300001"],"award-info":[{"award-number":["LR24H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422068"],"award-info":[{"award-number":["82422068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20814"],"award-info":[{"award-number":["U24A20814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jpha.2025.101335","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:08:32Z","timestamp":1746778112000},"page":"101335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Lingfeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2025.101335_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jpha.2025.101335_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2025.101335_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jpha.2025.101335_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116579","article-title":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","volume":"275","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101335_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2025.101335_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.106.025536","article-title":"Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor","volume":"70","author":"Chen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101335_bib8","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1073\/pnas.0710468105","article-title":"Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking","volume":"105","author":"Hellmuth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.jpha.2025.101335_bib9","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: Current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib10","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib12","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpha.2025.101335_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpha.2025.101335_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2025.101335_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.jpha.2025.101335_bib17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/ptr.8185","article-title":"Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"39","author":"Lu","year":"2025","journal-title":"Phytother. Res."},{"key":"10.1016\/j.jpha.2025.101335_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/aps.2012.90","article-title":"Natural products possessing protein tyrosine phosphatase 1B (PTP1B) inhibitory activity found in the last decades","volume":"33","author":"Jiang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jpha.2025.101335_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrd895","article-title":"Protein tyrosine phosphatase 1B inhibitors for diabetes","volume":"1","author":"Johnson","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2025.101335_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bmcl.2010.11.117","article-title":"Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs","volume":"21","author":"Scott","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jpha.2025.101335_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chembiol.2010.10.015","article-title":"SHP2 is a target of the immunosuppressant tautomycetin","volume":"18","author":"Liu","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jpha.2025.101335_bib22","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1021\/jm400474r","article-title":"Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.apsb.2020.10.021","article-title":"A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jpha.2025.101335_bib24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jpha.2025.101335_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jpha.2025.101335_bib26","doi-asserted-by":"crossref","first-page":"17221","DOI":"10.1021\/acs.jmedchem.1c01287","article-title":"Discovery of a novel androgen receptor antagonist manifesting evidence to disrupt the dimerization of the ligand-binding domain via attenuating the hydrogen-bonding network between the two monomers","volume":"64","author":"Fu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib27","doi-asserted-by":"crossref","first-page":"13841","DOI":"10.1021\/acs.jmedchem.1c01227","article-title":"Discovery of a novel Fusarium graminearum mitogen-activated protein kinase (FgGpmk1) inhibitor for the treatment of Fusarium head blight","volume":"64","author":"Fu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib28","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.jpha.2025.101335_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.gpb.2018.03.007","article-title":"Discovery of novel androgen receptor ligands by structure-based virtual screening and bioassays","volume":"16","author":"Zhou","year":"2018","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.jpha.2025.101335_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/13543776.2013.743995","article-title":"Tanshinone II-A: New perspectives for old remedies","volume":"23","author":"Xu","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jpha.2025.101335_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.041","article-title":"Cardiovascular actions and therapeutic potential of tanshinone IIA","volume":"220","author":"Gao","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jpha.2025.101335_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","article-title":"Clinical development of histone deacetylase inhibitors as anticancer agents","volume":"45","author":"Drummond","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jpha.2025.101335_bib33","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.1021\/acs.jmedchem.8b01455","article-title":"Structural basis of sirtuin 6 inhibition by the hydroxamate trichostatin A: Implications for protein deacylase drug development","volume":"61","author":"You","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74276","article-title":"Molecular features underlying differential SHP1\/SHP2 binding of immune checkpoint receptors","volume":"10","author":"Xu","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.jpha.2025.101335_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jpha.2025.101335_bib36","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/2159-8290.CD-23-0383","article-title":"SHP2: A pleiotropic target at the interface of cancer and its microenvironment","volume":"13","author":"Sodir","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpha.2025.101335_bib37","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101335_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe2967","article-title":"Druggable cancer phosphatases","volume":"13","author":"Vainonen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jpha.2025.101335_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2020.09.002","article-title":"Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation","volume":"183","author":"Zhu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101335_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06814-w","article-title":"Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2","volume":"9","author":"P\u00e1dua","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177925001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177925001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:32:35Z","timestamp":1776166355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177925001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2095177925001522"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101335","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}],"article-number":"101335"}}